- Oral presentation
- Open Access
Prognostic impact of late gadolinium enhancement cardiac magnetic resonance in the risk stratification of heart transplant patients
© Pedrotti et al. 2016
- Published: 27 January 2016
- Cardiac Magnetic Resonance
- Late Gadolinium Enhancement
- Left Ventricular Mass
- Major Cardiovascular Adverse Event
- Cardiac Allograft Vasculopathy
The aim of the present study was to assess the association of the presence and amount of late gadolinium enhancement (LGE) at cardiac magnetic resonance (CMR) with cardiovascular adverse events in patients who survived the first year after cardiac transplantation (HTx).
We enrolled 48 patients (mean age, 54.7 ± 14.6 years; 37 men) at various stages after HTx (median 9.88 yrs). All patients underwent standard CMR at 1.5 T, images were acquired with retrospective ECG gating and during repeated single breath-holds. Balanced steady-state free precession were used to obtain cine images (echo time/repetition time, 1.6/3.2 ms; flip angle, 60°; pixel size, 2.4 × 1.4 mm, slice thickness 8 mm, gap 2 mm) in three long-axis planes and in contiguous short-axis slices. LGE images were acquired in matching short-axis and long axis planes starting 10 min after intravenous injection of gadolinium-DTPA (Schering©, Berlin, Germany; 0.15 mmol/kg) and using a segmented inversion-recovery gradient echo sequence. The primary endpoint was a composite of first occurrence of major cardiovascular adverse events which required hospitalization (MACE): CV death, congestive heart failure, redo transplant, arrhythmias requiring hospitalization (high degree A-V block, sustained supraventricular tachyarrhythmias, sustained ventricular tachycardia, bradycardia requiring pace-maker implantation), coronary revascularization, the secondary endpoints were all-cause death and cardiovascular death. Survival of patients was estimated by Kaplan-Meier analysis, for each end point Cox multivariate models were constructed.
Myocardial LGE was detected in 26 patients (54%) with a median amount of 9.16 g (IQR 3.01 to 21.21) corresponding to 6.4% (IQR 2. 3 to 13.25) of LV mass. Cardiac allograft vasculopathy (CAV) was diagnosed in 54% LGE positive and 23% LGE negative patients (p = 0.057). Primary and secondary end-points were recorded during the follow-up period median 5.16 years (IQR 4.33 to 6.52). Ten patients died and 26 were readmitted because of MACE. LGE presence at CMR was associated with an increased risk of sustaining an index event during follow up shown by the Kaplan-Meier survival curves (Figure, logrank test p = 0.003). Multivariate Cox analysis identified as independent predictors of MACE a diagnosis of CAV (HR 3.63;p = 0.0039), left ventricular end systolic volume index (HR1.04; p = 0.008), LGE mass (HR1.04;p = 0.0007), LGE % of left ventricular mass (HR1.083; p = 0.0002). Independent predictors of all-cause death were CAV (HR 6.33;p = 0.0201), LGE mass (HR1.04; p = 0.005), LGE % of left ventricular mass (HR1.075; p = 0.007) whereas cardiovascular death was predicted by CAV (HR 10.8; p = 0.0263) and LGE mass (HR1.04; p = 0.0037).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.